Background The incidence of the neonatal abstinence syndrome, a drug-withdrawal
syndrome that most commonly occurs after in utero exposure to opioids, is known to have …

Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome in newborns
caused primarily by in utero exposure to opioids. In the United States, the incidence of NAS …

BACKGROUND: The national incidence of neonatal abstinence syndrome (NAS) has
increased with the opioid epidemic in the United States. The impact of pharmacologic …

Importance Neonatal abstinence syndrome, which occurs as a result of in utero opioid
exposure, affects between 6.0 and 20 newborns per 1000 live US births. There is substantial …

Objective: Neonatal abstinence syndrome (NAS) is a drug withdrawal syndrome
experienced by opioid-exposed infants. There is no standard treatment for NAS and surveys …

Objective: Neonatal abstinence syndrome (NAS), a postnatal opioid withdrawal syndrome,
increased threefold from 2000 to 2009. Since 2009, opioid pain reliever prescriptions and …

Neonates exposed prenatally to opioids will often develop a collection of withdrawal signs
known as neonatal abstinence syndrome (NAS). The incidence of NAS has substantially …

BACKGROUND: Neonatal abstinence syndrome (NAS) is a postnatal opioid withdrawal
syndrome. Factors associated with development of the syndrome are poorly understood; …

BACKGROUND AND OBJECTIVES: Neonatal abstinence syndrome (NAS) occurs after in
utero exposure to opioids, but outcomes after the postnatal period are unclear. Our …

Objective Standardized practices for the management of neonatal abstinence syndrome
(NAS) are associated with shorter lengths of stay, but optimal protocols are not established …